Cellular Biomedicine Group (CBMG) Misses Q2 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
Go back to Cellular Biomedicine Group (CBMG) Misses Q2 EPS by 7c
August 14, 2015 7:00 AM EDT
SHANGHAI, China and PALO ALTO, Calif., Aug. 14, 2015 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biomedicine firm engaged in the development of effective stem cell therapies for degenerative diseases and immunotherapies for cancer, today reported financial results and business highlights for the quarter and six months ended June 30, 2015.
"I am pleased with our second quarter progress in reaching certain planned milestones and in strengthening both our business and technological advantages," said Dr. William (Wei) Cao, Chief Executive Officer of Cellular Biomedicine Group. "In addition to our international-standard... More
August 14, 2015 7:00 AM EDT
SHANGHAI, China and PALO ALTO, Calif., Aug. 14, 2015 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biomedicine firm engaged in the development of effective stem cell therapies for degenerative diseases and immunotherapies for cancer, today reported financial results and business highlights for the quarter and six months ended June 30, 2015.
"I am pleased with our second quarter progress in reaching certain planned milestones and in strengthening both our business and technological advantages," said Dr. William (Wei) Cao, Chief Executive Officer of Cellular Biomedicine Group. "In addition to our international-standard... More
